Rofecoxib has different effects on chemokine production in colorectal cancer cells and tumor immune splenocytes
Autor: | Alastair J.M. Watson, Jehad Zweiri, Alice J. Walmesley, Stephen E. Christmas |
---|---|
Rok vydání: | 2007 |
Předmět: |
Cancer Research
Chemokine Colorectal cancer medicine.medical_treatment Immunology Gene Expression Dinoprostone Monocytes Lactones Mice Immune system Cell Line Tumor Splenocyte Immunology and Allergy Medicine Animals Sulfones Rofecoxib Cell Proliferation Pharmacology Mice Inbred BALB C biology Cyclooxygenase 2 Inhibitors business.industry Cell growth Immunotherapy medicine.disease Cyclooxygenase 2 biology.protein Cancer research Female Cyclooxygenase Chemokines business Colorectal Neoplasms Spleen medicine.drug |
Zdroj: | Journal of immunotherapy (Hagerstown, Md. : 1997). 30(6) |
ISSN: | 1524-9557 |
Popis: | Cyclooxygenase-2 (COX-2) is overexpressed in colon tumors. Its main product is the immunosuppressive prostaglandin PGE2 that aids tumor immune escape. In this study, we analyzed mechanisms of action of the COX-2 inhibitor rofecoxib on the immune response to colorectal cancer in an animal model. The murine colorectal cancer cell line MC26, and splenocytes from BALB/c mice immune to irradiated MC26 cells, were incubated with rofecoxib or PGE2. In MC26 cells, 100 nM rofecoxib caused a complete abrogation of PGE2 production and inhibited cell proliferation. Splenocytes from tumor immune mice showed a 300% (P0.01) increase in proliferation in response to irradiated MC26 cells, amplified to 450% (P0.01) by 1 microM rofecoxib (n=3). MC26 cells incubated with 1 microM rofecoxib showed increased gene expression of CCL3, CCL5, and CCL20 (P0.01). enzyme-linked immunosorbent assay tests also showed increased production of CCL5 and CCL20 (P0.01). PGE2 reversed this effect causing a 40% reduction in chemokine gene expression (n=3). In contrast, splenocytes from naive BALB/c mice stimulated with irradiated MC26 cells had only a marginal chemokine response to rofecoxib. PGE2 caused a 50% down-regulation of CCL5 and CCL20 at the gene level (n=2) and 30% and 40% reduction of CCL3, CCL4, CCL5, and CCL20 at the protein level (n=2). Hence rofecoxib has a 2-fold effect upon the immune response to MC26 cells, by enhancing production of chemokines chemotactic for dendritic cells and also reducing PGE2-mediated inhibition of lymphoproliferation. Together, these may be sufficient for an effective TH1-mediated antitumor response. Rofecoxib may have potential as an addition to existing immunotherapy strategies. |
Databáze: | OpenAIRE |
Externí odkaz: |